Shares of Faron Pharmaceuticals Oy (LON:FARN – Get Free Report) reached a new 52-week low during trading on Wednesday . The stock traded as low as GBX 35.70 and last traded at GBX 35.70, with a volume of 53907 shares trading hands. The stock had previously closed at GBX 39.50.
Faron Pharmaceuticals Oy Price Performance
The stock’s fifty day moving average is GBX 40.78 and its two-hundred day moving average is GBX 44.01. The stock has a market capitalization of £77.09 million, a P/E ratio of -1.72 and a beta of 1.12. The company has a debt-to-equity ratio of 155.01, a current ratio of 2.40 and a quick ratio of 1.09.
About Faron Pharmaceuticals Oy
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.
See Also
- Five stocks we like better than Faron Pharmaceuticals Oy
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
